Registry of Lobbyists
Total Number of Communication Reports: 28
Monthly communication reports in the last 6 months: 0
| Subject matters | Details | Categories |
|---|---|---|
|
Health, Research and Development
|
Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
|
Policies or Program
|
|
Economic Development, Health, Internal Trade, Research and Development
|
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine.
|
Policies or Program
|
|
Health
|
Engage the government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
|
Policies or Program
|
|
Health
|
Engage with government to strengthen the Priority Review of Drug Submissions process.
|
Policies or Program
|
|
Health, Privacy and Access to Information
|
Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs.
|
Regulation
|
|
Health, Internal Trade, Research and Development
|
Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace.
|
Policies or Program
|
|
Health
|
Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines.
|
Policies or Program
|
|
Health, Privacy and Access to Information, Research and Development, Science and Technology
|
Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development.
|
Legislative Proposal, Bill or Resolution
|
|
Health, International Trade, Justice and Law Enforcement
|
Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation.
|
Legislative Proposal, Bill or Resolution
|
|
Health, Intellectual Property, Research and Development
|
Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.
|
Regulation
|
|
Economic Development, Health, Research and Development
|
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
|
Policies or Program
|
|
Consumer Issues, Economic Development, Government Procurement, Health, Research and Development
|
Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR.
|
Policies or Program
|
|
Economic Development, Health, Internal Trade, Justice and Law Enforcement
|
Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines.
|
Policies or Program
|
|
Health
|
The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements.
|
Policies or Program
|
Address:
100 Milverton Drive
Suite 800
Mississauga, ON L5R 4H1
Canada
Telephone number:
905-819-3000
Web address:
http://ca.gsk.com/
Ryan Lock, Lead - Federal Affairs and Public Policy
GlaxoSmithKline Inc. is not a coalition.
The activities of GlaxoSmithKline Inc. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Sheamus Murphy | Public offices held
Firm: Counsel Public Affairs Inc.